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Systemic sclerosis (SSc) is a clinically heterogeneous autoim-
mune disease characterized by mutually exclusive autoantibodies
directed against distinct nuclear antigens. We examined HLA asso-
ciations in SSc and its autoantibody subsets in a large, newly
recruited African American (AA) cohort and among European
Americans (EA). In the AA population, the African ancestry-
predominant HLA-DRB1*08:04 and HLA-DRB1*11:02 alleles were
associated with overall SSc risk, and the HLA-DRB1*08:04 allele
was strongly associated with the severe antifibrillarin (AFA) anti-
body subset of SSc (odds ratio = 7.4). These African ancestry-
predominant alleles may help explain the increased frequency
and severity of SSc among the AA population. In the EA
population, the HLA-DPB1*13:01 and HLA-DRB1*07:01 alleles
were more strongly associated with antitopoisomerase (ATA)
and anticentromere antibody-positive subsets of SSc, respec-
tively, than with overall SSc risk, emphasizing the importance
of HLA in defining autoantibody subtypes. The association of
the HLA-DPB1*13:01 allele with the ATA+ subset of SSc in both
AA and EA patients demonstrated a transancestry effect. A
direct correlation between SSc prevalence and HLA-DPB1*13:01
allele frequency in multiple populations was observed (r =
0.98, P = 3 × 10−6). Conditional analysis in the autoanti-
body subsets of SSc revealed several associated amino acid
residues, mostly in the peptide-binding groove of the class II
HLA molecules. Using HLA α/β allelic heterodimers, we bioin-
formatically predicted immunodominant peptides of topoiso-
merase 1, fibrillarin, and centromere protein A and discovered
that they are homologous to viral protein sequences from
the Mimiviridae and Phycodnaviridae families. Taken together,
these data suggest a possible link between HLA alleles,
autoantibodies, and environmental triggers in the pathogenesis
of SSc.
scleroderma | HLA | autoantibodies | molecular mimicry | mimivirus
Author contributions: P.G., D.L.K., and E.F.R. designed research; P.G., S.A.S., T.A., S.E.B.,
D.S., P.J.S., S.C.C., J.C.M., and E.F.R. performed research; P.G., T.A., N.D.M., A.A.S., M.D.M.,
A.D., A.R.B., R.T.D., T.A.M., P.S.R., R.M.S., V.D.S., J.V., V.H., L.A.S., E.S., D.K., J.K.G., B.K.,
L.A.C., H.G., C.T.D., E.J.B., S.L.B., V.K.S., K.D.K., L.C., S.K., R.J., M.T., A.G., B.D.K., A.A.,
C.R., F.M.W., and F.B. contributed new reagents/analytic tools; P.G., S.A.S., T.A., S.E.B.,
and E.F.R. analyzed data; and P.G., S.A.S., A.A.S., M.D.M., A.D., A.R.B., D.S., R.T.D., P.S.R.,
R.M.S., V.D.S., J.V., V.H., L.A.S., E.S., D.K., J.K.G., B.K., L.A.C., H.G., C.T.D., E.J.B., S.L.B.,
V.K.S., K.D.K., L.C., S.K., R.J., M.T., A.G., B.D.K., P.J.S., S.C.C., J.C.M., A.A., C.R., F.M.W.,
D.L.K., F.B., and E.F.R. wrote the paper.y
Reviewers: M.J.D., Massachusetts General Hospital Center for Human Genetic Research;
S.G., Center of Experimental Rheumatology; and R.D.I., University of Toronto. y
Competing interest statement: M.D.M. received consulting fees from Mitsubishi Tanabe,
Astellas, Boehringer Ingelheim, Gerson Lehrman Group, Smart Analyst, and Guidepoint
Global. R.T.D. received consulting fees from Eicos Sciences. D.K. received consulting
fees from Actelion, Bristol-Myers Squibb, CSL Behring, Inventiva, EMD Merck-Serono,
Sanofi-Aventis, GlaxoSmithKline, Corbus, Cytori, UCB, Bayer, Boehringer Ingelheim, and
Genentech-Roche, and research support from Bayer, Bristol-Myers Squibb, and Pfizer, and
owns stock or stock options in Eicos Sciences, Inc. (CiViBioPharma, Inc.). L.A.S. received
consulting fees from Axon Pharma. H.G. received consulting fees from Pfizer, AbbVie,
Actelion, and Horizon Pharmaceuticals. C.T.D. received research support from Gilead,
Actelion, and Cytori. V.K.S. received research support from AbbVie. E.J.B. received con-
sulting fees from Genentech. L.C. received consulting fees or served on the board of
Reata, Bristol-Myers Squibb, Boehringer-Ingelheim, Eicos, and Mitsubishi Tanabe. S.L.B.
and M.J.D. are coauthors on a 2015 research article.y
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).y
1 To whom correspondence may be addressed. Email: dan.kastner@nih.gov or pravitt.
gourh@nih.gov.y
2 Deceased December 15, 2018.y
3 F.M.W., D.L.K., F.B, and E.F.R. contributed equally to this work.y
This article contains supporting information online at https://www.pnas.org/lookup/suppl/
doi:10.1073/pnas.1906593116/-/DCSupplemental.y
First published December 23, 2019.
552–562 | PNAS | January 7, 2020 | vol. 117 | no. 1 www.pnas.org/cgi/doi/10.1073/pnas.1906593116
M
ED
IC
A
L
SC
IE
N
CE
S
Significance
HLA alleles have previously been implicated with scleroderma
risk, but, in this study, using a European American ances-
tral cohort and a newly recruited large cohort of African
Americans, we comprehensively define the HLA alleles and
amino acid residues associated with scleroderma. Scleroderma
is characterized by mutually exclusive and specific autoanti-
bodies. We demonstrated ancestry-predominant HLA alleles
that were much more strongly associated with autoanti-
body subsets of scleroderma than with the overall risk of
SSc. We bioinformatically predicted immunodominant pep-
tides of self-antigens and demonstrated homology of these
peptides with viral protein sequences from Mimiviridae and
Phycodnaviridae families. Our findings suggest the hypothesis
that scleroderma-specific autoantibodies may arise through
molecular mimicry, driven by the interaction of specific viral
antigens with corresponding HLA α/β heterodimers.
Systemic sclerosis (scleroderma, SSc) is a systemic autoim-mune disease that is clinically heterogeneous and is char-
acterized by progressive thickening of the skin and internal
organs, leading to morbidity and mortality. A hallmark of SSc
is the presence of circulating antinuclear antibodies (ANA),
which are observed in 90 to 95% of patients (1). Anticen-
tromere antibody (ACA), antitopoisomerase I antibody (ATA),
anti-U3-ribonucleoprotein antibody (fibrillarin, AFA), and anti-
RNA polymerase III antibody (ARA) are the common autoan-
tibodies reported in SSc and are mutually exclusive and
specific for SSc (2, 3). These autoantibodies are associated
with distinct patterns of skin and internal organ involvement
and are markers of prognosis and survival (4–6). Compared
with European Americans (EA), African Americans (AA) have
a higher prevalence of ATA and AFA and also tend to
have a more severe phenotype comprising diffuse skin involve-
ment and greater interstitial lung disease, leading to increased
mortality (5, 7–10).
Genetic factors, along with environmental factors, contribute
to the risk of SSc with HLA genes reported to have the strongest
influence on SSc susceptibility, and these alleles have an even
stronger effect within the SSc-specific autoantibody subsets (11–
24). These HLA alleles encode variations in the antigen-binding
grooves of the HLA molecules that determine their binding
affinity for specific antigens presented to T helper cells (25).
Aberrant self-peptide or foreign peptide presentation via class
II HLA molecules on the antigen-presenting cells (APCs) leads
to activation of autoreactive T helper cells that play a cru-
cial role in activation of B cells, autoantibody formation, and
autoimmunity induction. Thus, HLA alleles coding for a spe-
cific antigen-binding groove sequence on the APCs recognize
a specific self-peptide causing activation of T helper cells and
production of autoantibodies.
HLA-mediated presentation of foreign antigens can activate
autoantigen-specific T cells either by presenting peptides derived
from self-proteins or by presenting peptides that are homologous
to self-antigens but derived from microbial proteins. This mech-
anism, whereby the amino acid sequence of a microbial peptide
is homologous to the peptide sequence from a self-protein, thus
causing activation of T helper cells and leading to B cell acti-
vation and autoantibody production against the self-protein, is
called molecular mimicry (26). Molecular mimicry has been
proposed in the pathogenesis of several autoimmune diseases,
including multiple sclerosis, type 1 diabetes mellitus, spondy-
loarthropathies, Graves’ disease, systemic lupus erythematosus
(SLE), and SSc (27–33). For instance, Epstein–Barr virus, a
ubiquitous human DNA virus, exhibits molecular mimicry with
common SLE self-antigens (30). Presence of viruses in SSc
tissues and viral infections acting as a trigger for autoimmu-
nity have been proposed as environmental risk factors in the
pathogenesis of SSc (33–35).
Given the potential importance of the HLA region and the
strong genetic risk it confers in SSc, we investigated the rela-
tionships between genetic HLA associations, autoantibodies, and
autoantigens, and identified candidate foreign peptides with
homology to autoantigens, which might promote SSc pathogen-
esis through molecular mimicry. AA SSc patients were obtained
from the Genome Research in African American Scleroderma
Patients (GRASP) cohort that was created to enroll a large
number of AA patients with SSc for conducting systematic
and comprehensive genetic studies (8, 36). Genotypes from 2
cohorts of AA and EA ancestries were used to impute HLA
classical alleles of 3 class I and 5 class II genes, which were
evaluated for association with SSc and common SSc-specific
autoantibodies. In the AA SSc cohort, we identified 2 African
ancestry-predominant alleles that could explain, at least in part,
the increased SSc frequency and severity observed in AAs. Upon
analyzing the autoantibody subsets of SSc, an even stronger
and specific HLA allele association was observed in both the
AA and EA cohorts. Pairs of HLA molecule alpha and beta
chains (HLA α/β heterodimers) were used to bioinformatically
predict immunodominant peptides derived from the specific self-
antigens that bind these HLA molecules. Remarkably, these
immunodominant peptides demonstrated significant sequence
homology with peptides derived from viruses in the Mimiviridae
and Phycodnaviridae families, suggesting potential molecular
mimicry.
Results
SSc Patients and Population Stratification. To identify HLA alleles
associated with SSc, we examined 662 AA SSc patients and 946
AA controls enrolled in the GRASP cohort along with 723 EA
SSc patients and 5,347 EA controls obtained from the database
of Genotypes and Phenotypes (dbGaP) (SI Appendix, Table S1).
The gender and autoantibody information for the AA and EA
SSc patients is shown in SI Appendix, Table S2. Principal compo-
nent (PC) analyses (PCAs) were performed, and the top 10 PCs
were used as covariates to correct for population stratification
in the association analyses for both the AA and EA populations
individually (SI Appendix, Fig. S1).
Classical HLA Allele Imputation. To assess imputation accuracy
in the AA cohort, we compared the HLA
∗
IMP:03 allele con-
cordance with exome sequence-based types from 763 GRASP
individuals, both SSc and controls, using the HLA
∗
PRG:LA
software (37). The concordance rates for class I and class II
HLA alleles present at minor allele frequency of >1% were
96% or higher (SI Appendix, Table S3). The allele frequencies
in both AA and EA SSc cases and controls for the HLA-A,
HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-
DPA1, and HLA-DPB1 genes are presented in SI Appendix,
Tables S4 and S5.
Classical HLA Allele Associations with SSc. In 662 AA SSc cases
and 946 controls, 2 independent class II HLA alleles were
significantly associated with AA SSc after correcting for popu-
lation stratification (Table 1 and SI Appendix, Fig. S2). In AA
SSc, a predominantly African ancestral allele, HLA-DRB1
∗
08:04
was the most strongly SSc-associated, with an odds ratio (OR)
of 3.2. A conditional regression analysis accounting for the
effect of HLA-DRB1
∗
08:04 allele identified a second African-
predominant allele, HLA-DRB1
∗
11:02, which was independently
associated with SSc, with an OR of 2.3 (Table 1).
In 723 EA SSc cases and 5,437 controls, 3 independent
HLA classical alleles, HLA-DQB1
∗
02:02, HLA-DPB1
∗
13:01,
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Table 1. Logistic regression and conditional analysis of HLA classical alleles in AA SSc
Frequency (%)† Unconditioned Conditioned
HLA allele (SSc/Ctrls) OR (95% CI) P value OR (95% CI) P value
All SSc vs. controls HLA-DRB1*08:04 24.3/9.3 3.2 (2.4-4.2) 3.26 × 10−16 3.2 (2.4-4.2) 3.26 × 10−16‡
SSc = 662; control = 946 HLA-DQB1*03:19 18.4/8.8 2.4 (1.8-3.2) 2.45 × 10−8
HLA-DQB1*03:01 37/25.8 1.8 (1.4-2.2) 1.41 × 10−6
HLA-DRB1*07:01 11.5/20.0 0.6 (0.4-0.7) 2.72 × 10−6
HLA-DQA1*02:01 11.5/20.0 0.6 (0.4-0.7) 3.18 × 10−6
HLA-DRB1*11:02 13.6/7.1 2.2 (1.6-3.0) 9.39 × 10−6 2.3 (1.6-3.2) 1.84 × 10−6
HLA-DPA1*02:01 62.1/51.5 1.6 (1.3-1.9) 3.20 × 10−5
HLA-DPB1*13:01 16.9/9.7 1.9 (1.4-2.6) 3.21 × 10−5
AFA+ SSc vs controls HLA-DRB1*08:04 42.6/9.3 7.4 (4.9-11.3) 2.61 × 10−19 7.4 (4.9-11.3) 2.61 × 10−19‡
SSc = 129; control = 946 HLA-DQB1*06:09 20.9/6.6 3.8 (2.3-6.3) 1.37 × 10−6 4.1 (2.4-7.0) 2.04 × 10−6
HLA-DQB1*03:01 45.0/25.8 2.5 (1.7-3.6) 9.16 × 10−6
HLA-DQB1*03:19 22.5/8.8 3.0 (1.9-4.9) 2.53 × 10−5
HLA-DRB1*13:02 29.5/13.8 2.6 (1.7-4.0) 3.70 × 10−5
ATA+ SSc vs. controls HLA-DPB1*13:01 30.6/9.7 4.3 (2.9-6.3) 2.35 × 10−12 4.3 (2.9-6.3) 2.35 × 10−12‡
SSc = 183; control = 946 HLA-DQB1*02:01 7.7/25.1 0.3 (0.2-0.5) 1.10 × 10−8 0.3 (0.2-0.5) 2.17 × 10−7
HLA-DRB1*03:01 3.3/14.9 0.2 (0.1-0.5) 4.92 × 10−7
HLA-DQB1*03:01 43.7/25.8 2.3 (1.7-3.1) 2.64 × 10−6
HLA-DPA1*02:01 69.9/51.5 2.3 (1.6-3.2) 2.73 × 10−6
HLA-DRB1*08:04 21.3/9.3 2.8 (1.8-4.2) 8.13 × 10−6
HLA-DQA1*05:01 51.4/39.1 1.6 (1.2-2.2) 2.90 × 10−3 2.1 (1.5-3.0) 2.21 × 10−5
ARA+ SSc vs. controls None significant
SSc = 119; control = 946
ACA+ SSc vs. controls None significant
SSc = 64; control = 946
Independent associations by conditional regression analyses are shown in bold.
†Frequency of individuals with 1 or 2 alleles.
‡Unconditioned; common AA haplotype: HLA-DRB1*08:04/DQA1*05:01/DQB1*03:01.
and HLA-DRB1
∗
11:04, were significantly associated with SSc
(Table 2 and SI Appendix, Fig. S2). The most significantly asso-
ciated allele, HLA-DQB1
∗
02:02, was disease-protective, with an
OR of 0.5, whereas HLA-DPB1
∗
13:01 and HLA-DRB1
∗
11:04
were disease risk alleles, with ORs of 2.6 and 2, respec-
tively (Table 2). Conditioning on the final HLA model for
each ancestral population, neither the classical HLA alleles
nor the HLA region single nucleotide variants remained sig-
nificant at the statistical threshold (SI Appendix, Figs. S3 and
S4). None of the class I HLA alleles showed any statisti-
cally significant independent association with SSc in either the
AA or EA cohort.
Classical HLA Allele Associations within SSc Autoantibody-Positive
Subsets. SSc has highly specific and mutually exclusive autoan-
tibodies, and thus we hypothesized that the HLA allelic associ-
ations would be stronger within the SSc-specific autoantibody
subsets. We tested this hypothesis by stratifying the SSc sam-
ples into subsets of SSc-specific autoantibody-positive patients
and evaluating association of HLA alleles. In 129 AFA+ AA
SSc patients, the OR for HLA-DRB1
∗
08:04 increased from 3.2
(P = 3.26 × 10−16) in overall SSc to 7.4 (P = 2.61 × 10−19)
in the AFA+ subset (Table 1). Although not detected in over-
all SSc, HLA-DQB1
∗
06:09 was independently associated in the
AFA+ SSc subset. In 183 ATA+ AA SSc, HLA-DPB1
∗
13:01,
HLA-DQB1
∗
02:01, and HLA-DQA1
∗
05:01 were independently
associated with ATA+ SSc (Table 1). The association of HLA-
DPB1
∗
13:01 with ATA+ SSc was particularly strong (OR =
4.3) as compared to overall SSc (OR = 1.9). None of the
HLA classical alleles were statistically significantly associated
with SSc in 119 ARA+ AA SSc patients, nor in 64 ACA+
AA SSc.
AFA data were not reported for the EA SSc patients in
dbGaP, so we were unable to evaluate the AFA+ subset in
the EA SSc patients. In 115 ATA+ EA SSc patients, HLA-
DPB1
∗
13:01 and HLA-DRB1
∗
11:04 were independently associ-
ated in the EA ATA+ SSc patients (Table 2). Also, as seen
in AAs, the association of HLA-DPB1
∗
13:01 in ATA+ SSc
subset was much stronger (OR = 13.7, P = 1.47 × 10−24)
than its association with overall SSc in EAs (OR = 2.6,
P = 1.75 × 10−8; Table 2). Interestingly, as in the ARA+
SSc subset in AAs, none of the classical HLA alleles were sta-
tistically significantly associated with the ARA+ SSc subset in
EAs. In 238 ACA+ EA SSc, HLA-DRB1
∗
07:01, associated with
SSc protection, was the most statistically significantly associ-
ated allele, with OR = 0.1 and P = 4.79 × 10−20 (Table 2
and SI Appendix, Fig. S2). HLA-DRB1
∗
07:01, part of the HLA-
DRB1
∗
07:01/DQA1
∗
02:01/DQB1
∗
02:02 haplotype, is in strong
linkage disequilibrium (LD) with HLA-DQB1
∗
02:02 (r2 = 0.95),
and likely explains the association of HLA-DQB1
∗
02:02 with
overall SSc.
HLA-DPB1
∗
13:01 and SSc. HLA-DPB1
∗
13:01 was identified as a
strong risk allele in both the AA and EA ATA+ SSc; there-
fore, we examined whether HLA-DPB1
∗
13:01 was enriched in
the ATA+ SSc subset exclusively. In AAs, HLA-DPB1
∗
13:01 was
present in 11.7% of ATA− SSc and 9.7% of controls, which was
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Table 2. Logistic regression and conditional analysis of HLA classical alleles in EA SSc
Frequency (%)† Unconditioned Conditioned
HLA allele (SSc/Ctrls) OR (95% CI) P value OR (95% CI) P value
All SSc vs. controls HLA-DQB1*02:02 10.2/18.0 0.5 (0.4-0.6) 3.55 × 10−9 0.5 (0.4-0.6) 3.55 × 10−9‡
SSc = 723; Control = 5,437 HLA-DRB1*07:01 15.1/23.7 0.5 (0.4-0.7) 6.06 × 10−9
HLA-DQA1*02:01 15.8/24.3 0.6 (0.4-0.7) 1.04 × 10−8
HLA-DPB1*13:01 8.3/3.3 2.6 (1.9-3.5) 1.75 × 10−8 2.6 (1.9-3.6) 1.04 × 10−8
HLA-DRB1*11:04 10.5/4.7 2.2 (1.7-2.9) 9.25 × 10−8 2.0 (1.5-2.7) 1.04 × 10−8
HLA-B*44:03 5.1/9.7 0.5 (0.3-0.7) 4.72 × 10−6
HLA-DRB1*01:01 23.7/17.3 1.5 (1.2-1.8) 4.39 × 10−5
AFA+ SSc vs. controls Not tested
SSc = 0; control = 5,437
ATA+ SSc vs. controls HLA-DPB1*13:01 32.2/3.3 13.7 (8.9-21.0) 1.47 × 10−24 13.7 (8.9-21.0) 1.47 × 10−24‡
SSc = 115; control = 5,437 HLA-DRB1*11:04 25.2/4.7 6.3 (3.9-10.0) 8.62 × 10−12 6.5 (4.0-10.6) 1.59 × 10−11
HLA-DPA1*02:01 48.7/26.3 2.9 (2.0-4.2) 8.70 × 10−8
HLA-DPA1*01:03 54.8/32.6 2.7 (1.8-3.9) 4.65 × 10−7
ARA+ SSc vs. controls None significant
SSc = 123; control = 5,437
ACA+ SSc vs. controls HLA-DRB1*07:01 3.4/23.7 0.1 (0.05-0.2) 4.79 × 10−20 0.1 (0.05-0.2) 4.79 × 10−20‡
SSc = 238; control = 5,437 HLA-DQA1*02:01 4.6/14.5 0.1 (0.1-0.2) 4.85 × 10−18
HLA-DQB1*02:02 2.9/18.0 0.1 (0.1-0.3) 2.44 × 10−14
HLA-DQB1*05:01 42.4/22.3 2.3 (1.8-3.0) 4.21 × 10−9 2.0 (1.5-2.6) 2.93 × 10−6
HLA-DQA1*01:01 47.5/26.7 2.2 (1.7-2.9) 7.08 × 10−9
HLA-DRB1*01:01 34.5/17.3 2.2 (1.7-3.0) 1.32 × 10−7
HLA-DQA1*04:01 14.3/5.4 2.7 (1.8-4.0) 4.18 × 10−6 2.7 (1.8-4.0) 6.67 × 10−6
HLA-DQB1*03:03 2.1/8.9 0.2 (0.1-0.5) 6.29 × 10−6
HLA-DRB1*08:01 11.8/4.6 2.6 (1.7-3.9) 4.97 × 10−5
Independent associations by conditional regression analyses are shown in bold.
†Frequency of individuals with 1 or 2 alleles.
‡Unconditioned; Common EA haplotypes: HLA-DRB1*11:04/DQA1*05:01/DQB1*03:01 and HLA-DRB1*07:01/DQA1*02:01/DQB1*02:02.
statistically not different, whereas 30.6% of ATA+ SSc carried
it. Similarly in EAs, HLA-DPB1
∗
13:01 was present in 32.3% of
ATA+ SSc and only 3.8% of ATA− SSc and 3.3% of controls.
HLA-DPB1
∗
13:01 was not only enriched in the ATA+ SSc subset
but also had a higher frequency in the AA control population as
compared to the EA control population. Given the fact that AAs
have a higher incidence and prevalence of SSc, we next explored
SSc prevalence and HLA-DPB1
∗
13:01 allele frequency in several
populations around the world. We observed a direct correlation
between SSc prevalence in any given population and the HLA-
DPB1
∗
13:01 frequency, with a correlation coefficient of 0.98 and
P = 1.8 × 10−6 (Fig. 1 and SI Appendix, Table S6). Even after
removing the Choctaw population with the highest prevalence
of SSc, the correlation coefficient remained 0.81 (SI Appendix,
Fig. S5).
Classical HLA Allele Associations within SSc Autoantibody-Negative
Subsets. On observing the enrichment of HLA-DPB1
∗
13:01
in the ATA+ SSc subset, we systematically examined the
autoantibody-negative subsets for association with the subset-
specific independent HLA alleles. HLA-DRB1
∗
08:04 was sta-
tistically significantly associated in both the AFA+ and AFA−
subsets in the AA SSc. This was consistent with the strong
association of HLA-DRB1
∗
08:04 in overall AA SSc patients.
The other independent HLA associations identified in the
autoantibody-positive SSc subsets were not observed in the
autoantibody-negative SSc subsets, highlighting the specificity
of these associations with these SSc-specific autoantibodies (SI
Appendix, Tables S7 and S8).
Amino Acid Residue Associations with SSc Autoantibody Subsets.
We performed amino acid association analysis for each of
the class II HLA genes in the AA and EA SSc autoan-
tibody subsets. In the AFA+ AA SSc subset, HLA-DRB1
amino acid (aa) positions 74 and 189, which are in tight LD,
showed the strongest association, followed by aa position 71
(SI Appendix, Fig. S6A). In HLA-DQB1, aa positions 45 and
86 were independently associated with SSc risk in the AFA+
subset (SI Appendix, Fig. S6A). In the ATA+ AA SSc subset,
Fig. 1. Population frequency of HLA-DPB1*13:01 allele and SSc prevalence.
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HLA-DPB1 aa position 76, HLA-DQB1 aa positions 45 and 57,
and HLA-DQA1 aa position 34 were independently contribut-
ing toward SSc risk (SI Appendix, Fig. S6A). Interestingly, aa
position 45 on HLA-DQB1 was important for both the AFA+
and ATA+ SSc subsets in the AA population (SI Appendix,
Fig. S6A). In the ACA+ EA SSc subset, HLA-DRB1 aa posi-
tions 60, 16, 13, and 180, HLA-DQB1 aa positions 135 and
74, and HLA-DQA1 aa position 47 were independently asso-
ciated with SSc (SI Appendix, Fig. S6B). In the ATA+ EA
SSc subset, HLA-DPB1 aa position 76 was strongly associated
with SSc risk, similar to in the AA population. HLA-DRB1
aa positions 58 and 67 were also independently contributing
toward SSc risk in the ATA+ subset in EAs (SI Appendix,
Fig. S6B). We highlighted these independently associated aa
residues in 3-dimensional (3D) ribbon models of HLA-DRβ,
HLA-DQα, HLA-DQβ, and HLA-DPβ with a direct view of
the peptide-binding groove. All of the above-mentioned SSc-
associated amino acids were part of the peptide-binding groove
of class II HLA molecules, except for HLA-DRβ aa posi-
tions 180 and 189 and HLA-DQβ aa position 135 (Fig. 2 and
SI Appendix, Fig. S7).
Classification and Regression Tree. We used an established
exploratory method (Classification and Regression Tree
[CART]) as an alternative approach to identify interactions
among the classical HLA alleles in the autoantibody subsets
in the AA and EA populations. The alleles partitioning out
higher in the decision tree suggest greater importance than the
ones lower in the tree. In the ATA+ AA SSc subset, 30.6%
carried HLA-DPB1
∗
13:01, and, furthermore, 2 higher-order
HLA allelic interactions were identified. HLA-DPB1
∗
13:01−/
HLA-DQB1
∗
02:01+ was seen in 6% of patients, and HLA-
DPB1
∗
13:01−/HLA-DQB1
∗
02:01−/HLA-DQA1
∗
05:01+ was
seen in 33.3% of patients (Fig. 3A and SI Appendix, Fig. S8A).
In the AFA+ AA SSc subset, 42.6% carried HLA-DRB1
∗
08:04;
14% carried HLA-DRB1
∗
08:04−/HLA-DQB1
∗
06:09+, and
5.4% carried HLA-DRB1
∗
08:04−/HLA-DQB1
∗
06:09−/HLA-
DRB1
∗
13:04+ (Fig. 3A and SI Appendix, Fig. S8B). Taken
together, the susceptibility HLA alleles account for 64% of
ATA+ SSc patients and 62% of AFA+ SSc patients in the AA
population. Similar analysis performed in the EA ATA+ SSc sub-
set identified HLA-DPB1
∗
13:01+ (32.2%), HLA-DPB1
∗
13:01−/
HLA-DRB1
∗
11:04+ (20.9%), and HLA-DPB1
∗
13:01−/HLA-
DRB1
∗
11:04−/HLA-DQA
∗
03:01+ (4.3%), accounting for
53% of patients with risk alleles (Fig. 3B and SI Appendix,
Fig. S9A). Fifty-four percent of EA ACA+ SSc patients were
accounted for by HLA-DRB1
∗
07:01−/HLA-DQB1
∗
05:01+
(42%) and HLA-DRB1
∗
07:01−/HLA-DQB1
∗
05:01−/HLA-
DQA1
∗
04:01+ (11.7%) (Fig. 3B and SI Appendix, Fig. S9B).
The ORs from the CART analysis were comparable to
the multivariate logistic regression analyses shown in
Tables 1 and 2.
HLA Molecule α and β Chain-Pair Associations with SSc Autoan-
tibody Subsets. The HLA alleles encode for class II HLA
molecules that are composed of an alpha and a beta chain, and
the resulting 3D structure defines the nature of the peptides
that are effectively bound. We performed association analysis of
the HLA haplotypes for HLA-DQA1/DQB1, HLA-DPA1/DPB1,
and HLA-DRA1/DRB1 pairs within SSc autoantibody subsets to
identify HLA α/β heterodimers. In the AAs, conditional regres-
sional analysis identified 2 HLA α/β heterodimers independently
associated with the AFA+ SSc subset and 3 HLA α/β het-
erodimers associated with the ATA+ SSc subset (Table 3). In
the EAs, conditional regressional analysis identified 2 HLA α/β
heterodimers associated with the ATA+ SSc subset and 2 α/β
heterodimers associated with the ACA+ SSc subset (Table 3).
HLA-DRA1
∗
01:01/DRB1
∗
07:01 was protective for ACA+ SSc
subset in the EAs, and HLA-DQA1
∗
05:01/DQB1
∗
02:01 was pro-
tective for ATA+ SSc subset in the AAs. The other 7 indepen-
dently associated HLA α/β heterodimers were all associated with
increased SSc risk.
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Fig. 2. Ribbon model of the HLA-DR, HLA-DQ, and HLA-DP proteins with independently associated amino acid residues, based on PDB ID codes 6atf, 1s9v,
and 3lqz, respectively. (A) Scleroderma-associated aa positions in AAs; (B) Scleroderma-associated aa positions in EAs.
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Fig. 3. Pie charts of independently associated classical HLA alleles. Data from ATA+, AFA+, and ACA+ subsets in (A) AAs and (B) EAs.
Immunodominant Peptide Prediction. We explored the possibility
of whether nuclear self-antigens act as the source of peptides that
are being recognized and presented by these HLA molecules. We
utilized NetMHCIIpan 3.2 to identify class II HLA restricted pep-
tides using theHLAα/β heterodimers and the correlated SSc self-
antigens (topoisomerase I, fibrillarin, and centromere protein A
or B [CENPA/CENPB]) (38). Peptide sequences that had a bind-
ing affinity of <500 nM to 2 associated HLA α/β heterodimers
were selected. We bioinformatically identified immunodominant
peptides on 3 regions of topoisomerase I that bind the multi-
ple HLA risk α/β heterodimers in ATA+ SSc in the 2 ancestral
populations (SI Appendix, Table S9). A similar search for immun-
odominant peptides in the AFA+ subset identified 5 regions on
fibrillarin and, in the ACA+ subset, yielded 1 region on CENPA
and 7 regions on CENPB that were bioinformatically predicted to
bind the multiple HLA risk α/β heterodimers for the respective
autoantibody subsets (SI Appendix, Tables S10, S11A, and S11B).
Molecular Mimicry. Next, we explored homology between the
bioinformatically predicted immunodominant peptide sequences
and microbial protein sequences to assess whether the autoanti-
bodies observed in SSc may be induced by molecular mimicry.
The bioinformatically predicted immunodominant peptide
sequences from topoisomerase I (SI Appendix, Table S9) were
compared for homology with microbial protein sequence
databases. Several hundreds of homologous sequences were
identified in fungi (E value < 0.05) due to extensive similari-
ties between human and fungi topoisomerase I proteins. There
was no homology observed with bacterial sequences even at an
E value of <1. Remarkably, only one sequence in topoisomerase
I, “RQRAVALYFIDKLAL,” had high-quality matches in the
viral database at an E value of <0.05. These homologous pep-
tides were from viruses in the Mimiviridae family, part of the
nucleocytoplasmic large DNA virus (NCLDV) clade, and had
an extremely significant homology E value of 3.0 × 10−6 with
Hokovirus (Fig. 4 and SI Appendix, Table S12). Given these
findings, we examined the bioinformatically predicted immun-
odominant peptides from fibrillarin, CENPA, and CENPB for
homology within the viral protein sequence database. On com-
paring several dozens of bioinformatically predicted immun-
odominant peptides, only one peptide sequence in fibrillarin,
and another one in CENPA, had high-quality matches (E
value < 0.05) in the viral database (SI Appendix, Tables S10
and S11A). Fibrillarin sequence “GRDLINLAKKRTNII” and
CENPA sequence “LQEAAEAFLVHLFED” were homologous
to protein sequences from NCLDV in the Mimiviridae and
Phycodnaviridae families with E values of 0.004 and 0.01, respec-
tively (Fig. 4 and SI Appendix, Table S12). No high-quality
matches were found for any of the CENPB sequences (SI
Appendix, Table S11B).
These highly significant E values suggest that the homology
was unlikely to occur by chance. To test this hypothesis even
Table 3. Logistic regression and conditional analysis of HLA α/β heterodimers in SSc
autoantibody subsets
SSc case group (n) HLA α/β heterodimer OR (95% CI) P value
AA AFA+ SSc vs. controls DRA1*01:01/DRB1*08:04 7.4 (4.9-11.3) 2.6 × 10−19
SSc = 129; control = 946 DQA1*01:02/DQB1*06:09 4.6 (2.6-7.9) 4.0 × 10−7†
AA ATA+ SSc vs. controls DPA1*02:01/DPB1*13:01 4.8 (3.2-7.1) 8.4 × 10−14
SSc = 183; control = 946 DQA1*05:01/DQB1*02:01 0.2 (0.1-0.5) 5.3 × 10−6†
DQA1*05:01/DQB1*03:19 3.3 (2.0-5.5) 1.6 × 10−5†
EA ATA+ SSc vs. controls DPA1*02:01/DPB1*13:01 15.7 (10.1-24.2) 1.2 × 10−25
SSc = 115; control = 5437 DRA1*01:01/DRB1*11:04 6.4 (3.9-10.4) 2.9 × 10−11†
EA ACA+ SSc vs. controls DRA1*01:01/DRB1*07:01 0.1 (0.05-0.2) 4.8 × 10−20
SSc = 239; control = 5,437 DQA1*01:01/DQB1
∗
05:01 2.0 (1.5-2.6) 1.8 × 10−6†
†Significance upon conditioning on top associated α/β heterodimer(s).
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Source % Homology
Immunodominant Epitope 100 R Q R A V A L Y F I D K L A L
Hokovirus HKV1 93 R Q I A V A L Y F I D K L A L
Megavirus chiliensis 80 R Q I A T A L Y F I D K F A L
Megavirus viƟs 80 R Q I A T A L Y F I D K F A L
Powai lake megavirus 80 R Q I A T A L Y F I D K F A L
Klosneuvirus KNV1 80 R Q I A T A L Y F I D K F A L
Catovirus CTV1 80 R Q I A T A L Y F I D K F A L
Topoisomerase I
Sequence
Source % Homology
Immunodominant Epitope 100 G R D L I N L A K K R T N I I
Acanthamoeba polyphaga moumouvirus 65 D L I N L A K K I-- --N N I I
Saudi moumouvirus 65 D L I N L A K K I-- --N N I I
Moumouvirus Monve 65 D L I N L A K K I-- --N N I I
Fibrillarin
Sequence
Source % Homology
Immunodominant Epitope 100 L Q E A A E A F L V H L F E D
Dishui lake phycodnavirus 1 80 L Q E A A E A Y L T S L F E D
Sequence
CENPA
Exact match
ConservaƟve amino acid subsƟtuƟon
Ancestry
PosiƟon Sequence DRA1*01:01/DRB1*07:01 DRA1*01:01/DRB1*01:01
EA 94 LQEAAEAFLVHLFED 445.81 299.55
ACA+ SSc Subset (CENPA)
PepƟde Affinity (nM)
Ancestry
PosiƟon Sequence DPA1*02:01/DPB1*13:01 DRA1*01:01/DRB1*11:04
EA 473 RQRAVALYFIDKLAL 264.2 340.3
PosiƟon Sequence DPA1*02:01/DPB1*13:01 DQA1*05:01/DQB1*02:01
AA 473 RQRAVALYFIDKLAL 264.2 446.4
ATA+ SSc Subset
PepƟde Affinity (nM)
Ancestry
PosiƟon Sequence DRA1*01:01/DRB1*08:04 DRA1*01:01/DRB1*13:02
AA 197 GRDLINLAKKRTNII 81.2 304.3
AFA+ SSc Subset
PepƟde Affinity (nM)
@
A
B
C
D
E
F
G
H
I
Fig. 4. Bioinformatically derived immunodominant peptides and homologous viral protein identification. (A) Predicted immunodominant peptides in
topoisomerase I protein, (B) peptide sequences from microbial proteins homologous to topoisomerase I sequence, (C) 3D ribbon model of topoisomerase I
with the identified immunodominant peptide in pink, (D) predicted immunodominant peptides in fibrillarin protein, (E) peptide sequences from microbial
proteins homologous to fibrillarin sequence, (F) 3D ribbon model of fibrillarin protein with the identified immunodominant peptide in pink, (G) predicted
immunodominant peptides in CENPA, (H) peptide sequences from microbial proteins homologous to CENPA sequence, and (I) 3D ribbon model of CENPA
protein with the identified immunodominant peptide in pink. (These structures are based on PDB ID codes 1a35 for topoisomerase I, 2ipx for fibrillarin, and
3nqu for CENPA; @ in LD with DQA1*01:02/DQB1*06:09.)
more rigorously, we contrasted the E values from randomly gen-
erated peptides to act as negative comparators. One hundred
randomly generated 15-mer peptide sequences were compared
to the viral sequence database for homology. None of these
sequences matched any viruses from the Mimiviridae or Phy-
codnaviridae families (SI Appendix, Tables S13A and S13B).
Additionally, an arbitrary 15-mer peptide selected from serum
albumin residues 152 to 166, to act as a negative control for
self-antigen peptides (39), did not show any homology with
any viruses from the Mimiviridae or Phycodnaviridae families.
The topoisomerase I immunodominant peptide “RQRAVALY-
FIDKLAL” is part of the catalytic domain of the topoisom-
erase I enzyme and is highlighted in pink on the 3D structure
(Fig. 4C). The fibrillarin and CENPA immunodominant pep-
tides are also highlighted on their respective protein structures
(Fig. 4 F and I). Next, we compared the “RQRAVALYFID-
KLAL” sequence in topoisomerase I, “GRDLINLAKKRTNII”
sequence in fibrillarin, and “LQEAAEAFLVHLFED” sequence
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in CENPA for homology within the human protein database
and discovered that these peptide sequences were unique to
topoisomerase I, fibrillarin, and CENPA proteins, respectively,
with E values of <0.05 (SI Appendix, Tables S14A, S14B,
and S14C).
Bioinformatically Predicted Immunodominant Peptides in Other
Ancestries. We examined whether the bioinformatically pre-
dicted immunodominant peptides with homology to Mimiviridae
and Phycodnaviridae viruses that were identified in the AA
and EA SSc patients were also recognized by SSc-associated
HLA alleles in SSc patients of other ancestries. SSc-associated
HLA alleles in the ACA+ and ATA+ subsets in the Japanese,
Chinese, Thai, Turkish, Iranian, Mexican, and Choctaw Indian
populations were selected from published manuscripts (40–
45). Upon examining the HLA risk alleles for the ATA+
subset in these populations, the “RQRAVALYFIDKLAL”
sequence in topoisomerase I was predicted to bind with sig-
nificant affinity to HLA-DRB1
∗
15:02 in the Japanese and
Thai populations, HLA-DRB1
∗
08:02 in the Mexican popula-
tion, HLA-DRB1
∗
11:04 and HLA-DPB1
∗
13:01 in the Turkish
and Iranian populations, and HLA-DRB1
∗
16:02 in the Choctaw
Indian populations (SI Appendix, Table S15A) (40–44). Likewise,
the “LQEAAEAFLVHLFED” sequence in CENPA was pre-
dicted to bind with significant affinity to HLA-DQB1
∗
05:01 in
the Japanese and Chinese populations and HLA-DQB1
∗
03:01
in the Japanese population, which are the HLA risk alle-
les for the ACA+ subset in these populations (SI Appendix,
Table S15B) (40, 45).
Discussion
This is the largest genetic study of AA SSc patients identify-
ing African ancestry-predominant alleles, HLA-DRB1
∗
08:04 and
HLA-DRB1
∗
11:02, that increase SSc risk. We demonstrate that
an African ancestry HLA allele, HLA-DRB1
∗
08:04, is associated
with AFA that is common in the AA SSc patients and con-
fers a risk of 7.4-fold. A previously unreported allele in SSc,
HLA-DQB1
∗
06:09, confers a risk of 4.1-fold in the AFA+ subset,
independent of the effect of HLA-DRB1
∗
08:04. We also report
a very strong association of the HLA-DPB1
∗
13:01 allele with
the ATA+ subset of SSc that displays a transancestry effect. We
show that the HLA-DRB1
∗
07:01/DQA1
∗
02:01/DQB1
∗
02:02 hap-
lotype confers an extremely protective effect in the ACA+ EA
SSc subset with an OR of 0.1, and HLA-DRB1
∗
07:01 has been
reported to be protective for several other autoimmune diseases
as well (46–50). Notably, there were no class I HLA alleles iden-
tified independently of class II HLA allele association, placing
SSc firmly in the category of class II HLA disease. Lastly, the
bioinformatically predicted immunodominant peptides on topoi-
somerase I, fibrillarin, and CENPA had significant homology
to proteins from viruses in the Mimiviridae and Phycodnaviri-
dae families, suggesting a potential environmental link in SSc
pathogenesis.
An interesting observation in our study was the enrichment
of the HLA alleles in SSc-specific autoantibody subsets that
increased the risk severalfold. Supporting this hypothesis, we
identified autoantibody subset-specific HLA alleles that, while
not statistically significant in overall SSc, were significant in the
autoantibody subsets with increased ORs. An exception to this
was the strong association of HLA-DRB1
∗
11:02 found in over-
all SSc in the AA population but not identified in any of the
examined SSc-specific autoantibody subsets. On further analysis,
it seems that the association of HLA-DRB1
∗
11:02 was stronger
in individuals with a speckled nuclear staining pattern, and its
relevance to SSc will need to be further explored. The absence
of any statistically significant association in the ACA+ SSc sub-
set in the AAs was likely due to inadequate power because of
the small sample size, since the frequency of ACA in the AA
SSc patients is low (SI Appendix, Table S2). It is intriguing that
the ARA+ SSc subset did not yield any statistically significant
associations in either the AA or EA populations. This could
possibly be due to the small sample size, leading to inadequate
statistical power to detect an association. However, the ARA+
subset had a larger sample size than the ATA+ subset in EAs;
thus it is possible that ARA+ SSc may not be one homoge-
neous entity. Instead, the ARA+ SSc subset could potentially
represent a diverse collection of SSc phenotypes characterized
by cancer association, presence of SSc renal crisis, or aggres-
sive diffuse skin involvement. Perhaps further stratification of
the ARA+ subset would yield statistically significant HLA asso-
ciations. There is still a possibility that only non-HLA genes
increase SSc risk in the ARA+ subset, but the HLA genes
playing no role whatsoever in the pathogenesis of ARA+ SSc
is unlikely.
HLA-DPB1
∗
13:01 association with ATA+ SSc is very interest-
ing, and the allele is present in a third of the ATA+ patients
irrespective of African or European ancestry. This transances-
try effect of HLA-DPB1
∗
13:01 in AAs and EAs has previously
been reported in the Choctaw native American SSc patients,
who have a very uniform phenotype, with 95% ATA positivity
and 65% HLA-DPB1
∗
13:01 carrier frequency in the ATA+ sub-
set (51, 52). The Choctaw native American SSc patients have
not only the highest reported population carrier frequency of
the HLA-DPB1
∗
13:01 allele (45%) but also the highest reported
prevalence of SSc (51, 52). In both the AA and EA popu-
lations, HLA-DPB1
∗
13:01 frequency in the ATA− SSc sub-
sets was similar to the controls and not statistically significant.
This, along with the direct correlation of HLA-DPB1
∗
13:01 fre-
quency with SSc prevalence in various populations around the
world, suggests a distinct role this allele may be playing in
SSc pathogenesis. Interestingly, in the HLA-DPβ aa associa-
tion analyses, aa position 76 isoleucine was the only statistically
significant aa in both the AA and EA populations. It is possi-
ble that the HLA-DPβ aa position 76 isoleucine modifies the
peptide-binding groove to recognize specific peptides that are
presented by APCs to T helper cells, leading to an increase
in SSc risk.
We identified several SSc-associated aa residues in all of
the class II HLA genes, and most of them were part of the
peptide-binding groove. Amino acid leucine, at position 74, in
the peptide-binding groove was specific to HLA-DRB1
∗
08:04
and was in perfect LD with serine at position 189 outside of the
peptide-binding groove. These peptide-binding groove residue
changes might be leading to APC recognition of specific pep-
tides that, on presentation to T helper cells, lead to T helper
cell activation and, in turn, B cell activation, ultimately result-
ing in autoimmunity. The residues outside the peptide-binding
groove might play a role in altering the structure of the class
II HLA molecule or modifying the interaction of the class II
HLA molecule with the T cell receptor. Using CART analysis,
we identified multiple HLA alleles for each of the SSc-specific
autoantibody subsets (AFA+, ATA+, and ACA+) in both the
AA and EA populations, which account for 53–64% of the SSc
cases in each of these subsets.
Antibodies directed toward different nuclear or nucleolar self-
antigens are seen in 95% of SSc patients (1). In this study, we
explored the role of the class II HLA alleles and autoantigens
and thus proposed self-antigens as a likely source of peptides
that, once bound to the HLA molecules on APCs, are presented
to T helper cells. We bioinformatically predicted immunodomi-
nant peptides that were recognized by multiple HLA risk alleles
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for each of the SSc-specific autoantibody subsets. The topoiso-
merase I peptide sequence “RQRAVALYFIDKLAL” that was
bioinformatically predicted as an immunodominant peptide in
both AA and EA ATA+ subsets is part of the catalytic domain
of the molecule, unique to this protein and evolutionarily con-
served. Hu et al. (53) have identified peripheral T cell lines from
SSc patients recognizing the “RAVALYFIDKLA” peptide on
topoisomerase I.
Molecular mimicry has been invoked previously as a potential
mechanism driving autoimmunity in several diseases, includ-
ing cytomegalovirus in multiple sclerosis and Epstein–Barr
virus in lupus (27–30). We examined whether the bioinformat-
ically predicted immunodominant peptide sequences identified
in this study had homology to microbial protein sequences.
Remarkably, “RQRAVALYFIDKLAL” sequence in topoisom-
erase I, “GRDLINLAKKRTNII” sequence in fibrillarin,
and “LQEAAEAFLVHLFED” sequence in CENPA matched
sequences from viruses of the Mimiviridae and Phycodnaviri-
dae families that belong to the NCLDV clade, with an extremely
high confidence level (54). Mimiviruses and phycodnaviruses are
ubiquitous in aquatic environments, and humans are constantly
being exposed to these viruses (55, 56). These viruses cannot
infect human cells or replicate in them, but rather mimiviruses
infect amoeba and phycodnaviruses infect algae (57, 58). Even
though humans do not get infected with these viruses, phagocy-
tosis by macrophages of virus-infected amoeba or algae can lead
to processing of viral antigens and presentation via the class II
HLA receptor to T helper cells (57). Activated T cells recog-
nizing self-antigens with homology to viruses could arise from
activation of quiescent T cells with receptors specific for host
antigens resulting in autoreactive T cells. Alternatively, autoreac-
tive T cells could arise by T cell receptor poly-specificity. Peptide
recognition by T cell receptors is based on amino acid proper-
ties, and the binding motifs are degenerate, with only a small
sequence needed for recognition. Similarities in peptides at criti-
cal residues that bind to the class II HLA molecules could lead to
T cell cross-reactivity, ultimately leading to autoreactive T cells
(59–62). Mimivirus and phycodnavirus peptides that have homol-
ogy to topoisomerase I, fibrillarin, or CENPA could activate T
helper cells, which, in turn, activate B cells with receptors that
specifically recognize and target these nuclear antigens (topoi-
somerase I, fibrillarin, and CENPA, respectively). This could
lead to the formation of ATA, AFA, and ACA observed in
74.8% of AA and 65.8% of EA SSc. Our data indicate that gen-
eration of a particular autoantibody has a strong relationship
to class II HLA alleles, but the pathogenic potential of SSc-
specific autoantibodies is unclear, and their presence could be
an epiphenomenon. Constant exposure of the immune system
to these nuclear antigens could lead to chronic autoimmunity.
This raises an interesting hypothesis for a possible environ-
mental link in SSc pathogenesis. An increased occurrence of
antibodies against mimivirus collagen has been demonstrated
in rheumatoid arthritis patients, along with antibodies against
the mimivirus capsid protein L425 in a third of the rheumatoid
arthritis patients (63). It is also possible that molecular mimicry
to mimiviruses may just be an epiphenomenon not playing a
direct role in SSc pathogenesis (64). Testing SSc samples for anti-
bodies against mimivirus capsid protein would be an important
step to demonstrate patient exposure to these viruses.
These HLA findings validate our understanding of SSc as an
autoimmune disease and emphasize the relevance of class II
HLA genes in SSc pathogenesis. The heterogeneity observed
in SSc is best characterized by the robust HLA allelic associ-
ations demonstrated in the SSc-specific autoantibody subsets.
These SSc-specific autoantibodies correlate not only with spe-
cific HLA alleles but also with distinct clinical phenotypes and
disease outcomes (4–6). Stratifying SSc on the basis of autoan-
tibodies and HLA alleles together for research and clinical
trials may yield beneficial results. In the future, screening HLA-
DPB1
∗
13:01+ individuals for ANA and ATA could result in
early identification and therapeutic intervention to block the
development of SSc.
Materials and Methods
Patients and Controls. This study included 662 AA SSc patients enrolled from
23 academic centers throughout the United States under the GRASP consor-
tium with available genotype (Dataset S1) and serum SSc-specific autoanti-
body data (Dataset S2) (8, 36). The study was conducted in accordance with
the Declaration of Helsinki, and participating centers secured local ethics
committee approval prior to participant enrollment. All patients met the
1980 American College of Rheumatology (ACR) or the 2013 ACR/European
League Against Rheumatism classification criteria for SSc or had at least 3
of the 5 features of CREST syndrome (calcinosis, Raynaud’s phenomenon,
esophageal dysmotility, sclerodactyly, telangiectasias); 946 genetically sim-
ilar unrelated controls were obtained from the Howard University Family
Study, a population-based study of AA families and unrelated individuals
(65). All cases and controls provided written informed consent. Genotype
and phenotype data of 723 European ancestry SSc patients and 5,437 con-
trols genotyped on the same platform were extracted from dbGaP (SI
Appendix, Table S1). European ancestry SSc patients were a subset of those
reported by Radstake et al. (14).
Autoantibody Testing. Sera from the AA SSc patients were tested by a line
immunoassay for SSc profile autoantibodies (Euroimmun Euroline profile
kit). For the European ancestry SSc patients, reported autoantibody data
were extracted from dbGaP accession phs000357.v1.p1.
Genotyping. The AA SSc cases and controls were genotyped with the
Illumina Infinium Multi-Ethnic Global Array kit. High-quality genotypes
were imputed using the Michigan Imputation Server, and the required
6,114 markers were submitted to the HLA
∗
IMP:03 server for HLA impu-
tation. The European ancestry samples were genotyped on Illumina
Human610-Quadv1 B chip (SI Appendix).
PCA. For the 2 ancestral populations, PCA was used to evaluate the genetic
similarity of the cases with the controls, to remove outliers, and to correct
for residual dissimilarity separately (SI Appendix). Two-dimensional plots of
the first 2 principal components of the cases and controls in each study are
shown in SI Appendix, Fig. S1.
HLA Imputation. We selected the HLA
∗
IMP:03 tool to perform HLA impu-
tation in the AA samples because it has a multiethnic reference panel of
10,561 individuals that includes 568 of African ancestry (SI Appendix) (66).
We used available whole-exome sequence data for 763 of the AA samples
to determine their HLA alleles using HLA
∗
PRG:LA, allowing for comparison
of HLA
∗
IMP:03 imputed alleles with HLA
∗
PRG:LA sequence-based alleles
(37). For EA samples, SNP2HLA software and a mainly European ancestry
reference of 5,225 individuals were used to impute classical HLA alleles and
polymorphic HLA amino acids (67).
HLA Association and Conditional Analysis. HLA alleles with frequency less
than 0.01 were omitted, and a logistic regression association analysis was
performed under a dominant model classically used for identifying HLA alle-
les associated with diseases (68) (SI Appendix). Regressions were corrected
for genetic dissimilarity between the cases and the controls by including the
top 10 PCs as covariates. To account for strong LD in the region, independent
associations were identified by recursively including independent alleles as
covariates. The total number of classical HLA alleles tested for association
was 138 in both the populations, and there were 5 analyses conducted. Thus
a Bonferroni’s multiple test corrected significance threshold of P < 0.000072
was used for association analysis.
Amino Acid Analysis. Amino acid associations with SSc were evaluated with
a dominant model logistic regression analysis. Amino acids with frequency
less than 0.01 were omitted. The P value threshold was set as P < 0.000013
based on 800 amino acids tested across both population samples, multiplied
by 5 sets of analysis.
The 3D Protein Modeling. Protein Data Bank (PDB) ID codes 1a35, 2ipx,
3nqu, 6atf, 1s9v, and 3lqz were obtained for topoisomerase I, fibrillarin,
CENPA, HLA-DR, HLA-DQ, and HLA-DP, respectively. UCSF Chimera was used
to highlight individual aa positions (69).
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CART Analysis. CART analysis was performed to explore higher-order
interactions among the HLA alleles using CART 6.0, Salford Sys-
tems (70).
Bioinformatic Prediction of Immunodominant Peptides. An online computa-
tional tool, the NetMHCIIpan 3.2 server, was used to predict the binding of
15-mer peptide sequences within the protein of interest (topoisomerase I,
fibrillarin, or CENPA/CENPB) to the SSc-associated major histocompatibility
complex (MHC) class II α/β heterodimers within the respective autoanti-
body subsets. Peptides with a binding affinity of ≤ 500 nM and observed
in 2 of the SSc-associated HLA α/β heterodimers were prioritized as
immunodominant peptides (38).
Molecular Mimicry. The prioritized immunodominant peptide sequences
were entered into the National Center for Biotechnology Information
(NCBI) Basic Local Alignment Search Tool Standard Protein BLAST with the
organism set to human (taxid:9606) to identify homologous sequences in
other human proteins, and to fungi (taxid: 4751), bacteria (taxid: 2), and
virus (taxid: 10239) to find homologous microbial sequences. Significant
homology was defined by an E value of <0.05 (71).
Data Availability. The AA genotype data are available as Dataset S1, and
the corresponding phenotypic information is available as Dataset S2. The
EA dataset is available from dbGaP (SI Appendix, Table S1).
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